FDA

FDA Articles

Immunomedics shares were crushed on Friday after the firm received disappointing news from the FDA on its breast cancer treatment.
Akorn shares dipped on Wednesday after the company received a warning letter from the FDA regarding its Decatur, Illinois, manufacturing facility.
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
Spectrum Pharma shares dipped on Thursday after the firm announced a key update from the FDA on its treatment of neutropenia in breast cancer patients.
Although hemp has been removed from the FDA's list of controlled substances, the agency retains authority to review for safety products that use hemp.
Gritstone shares made a handy gain on Friday after the firm received a key update from the FDA.
The percentage of U.S. teens who report using vaping devices is on the rise. Year over year, use by high school seniors rose by a third in 2018. But there's also some good news on teen drug abuse in...
Eli Lilly shares rose slightly on Thursday after the company announced an FDA update on its treatment for systemic lupus erythematosus.
24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest of 2018.
GBT shares dipped on Friday after the company announced that it would be conducting a secondary offering. This offering comes on the heels of a key FDA approval.
Global Blood Therapeutics shares shot up on Monday after the company announced that it received an update from the FDA in regards to its sickle cell disease treatment.
Tonix Pharmaceuticals shares were up sharply on Thursday after the company announced an update from the FDA.
Rocket Pharmaceuticals shares dipped on Tuesday after the company gave an update from the FDA. While the update wasn’t negative, this seems to be a case of sell the news, as the stock is up 65% in...
Despite this crushing loss where we saw shares down about 41% on Monday, one analyst is still positive on the stock.
Zafgen shares were absolutely crushed on Monday after the company announced an update from the FDA.